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Acetylated tau inhibits chaperone-mediated
autophagy and promotes tau pathology
propagation in mice
Benjamin Caballero1,2,11,14, Mathieu Bourdenx 1,2,12,14, Enrique Luengo1,2,3,4, Antonio Diaz1,2,
Peter Dongmin Sohn5, Xu Chen5, Chao Wang 5, Yves R. Juste1,2, Susanne Wegmann 6,7, Bindi Patel1,2,
Zapporah T. Young8, Szu Yu Kuo8, Jose Antonio Rodriguez-Navarro 1,2,13, Hao Shao8, Manuela G. Lopez 3,4,
Celeste M. Karch 9, Alison M. Goate 10, Jason E. Gestwicki 8, Bradley T. Hyman 6, Li Gan5 &
Ana Maria Cuervo 1,2 ✉

Disrupted homeostasis of the microtubule binding protein tau is a shared feature of a set of
neurodegenerative disorders known as tauopathies. Acetylation of soluble tau is an early
pathological event in neurodegeneration. In this work, we ﬁnd that a large fraction of neuronal
tau is degraded by chaperone-mediated autophagy (CMA) whereas, upon acetylation, tau is
preferentially degraded by macroautophagy and endosomal microautophagy. Rerouting of
acetylated tau to these other autophagic pathways originates, in part, from the inhibitory
effect that acetylated tau exerts on CMA and results in its extracellular release. In fact,
experimental blockage of CMA enhances cell-to-cell propagation of pathogenic tau in a
mouse model of tauopathy. Furthermore, analysis of lysosomes isolated from brains of
patients with tauopathies demonstrates similar molecular mechanisms leading to CMA
dysfunction. This study reveals that CMA failure in tauopathy brains alters tau homeostasis
and could contribute to aggravate disease progression.
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ccumulation of the microtubule-stabilizing protein tau in
neuroﬁbrillary tangles is a hallmark of tauopathies,
including Alzheimer’s disease (AD) and frontotemporal
lobar degeneration1. Tau function is negatively regulated by different post-translational modiﬁcations (i.e., phosphorylation2–4
and acetylation5,6). Acetylation has been described as a pathogenic post-translational modiﬁcation of tau in brains from AD7,8
and related tauopathies patients5,6,9,10. Recently, acetylation sites
have been precisely mapped onto the Cryo-EM structure of tau
ﬁlaments from patients’ brain tissue11. Tau acetylation reduces its
binding to microtubules, promotes tau ﬁbrillization, reduces tau
degradation5,9, and contributes to tau-mediated synaptic
toxicity12. Although the emphasis on pathogenic tau clearance
has mostly focused on aggregated tau, tau acetylation on lysine
174 (K174) was identiﬁed as an early modiﬁcation in the soluble
fraction of AD patients13. Reducing tau acetylation at K174 rescues cognitive deﬁcits and tau-mediated neurodegeneration13,
suggesting that reducing soluble forms of tau is efﬁcient in
improving cognitive function14–16.
Tau pathology spreads in the brain following a predictable
pattern of progression17,18 attributed to cell-to-cell propagation of
pathogenic tau19,20. However, as tau lacks conventional secretion
signals21,22, the process of tau transmission between neighboring
neurons is still poorly understood. Enhanced acetyltransferase
activity in tauopathies has been shown to result in excess tau
secretion and spreading23. However, whether this is a consequence of direct tau acetylation or due to acetylation of other
cellular components remains unknown.
The ubiquitin-proteasome and the autophagic-lysosomal system have been implicated in tau clearance24,25 and both proteolytic systems have shown to be altered in neurodegenerative
disorders, including AD24,26,27. Previous reports from our group
and others have demonstrated tau degradation by macroautophagy, a process that requires the sequestration of cargo in
double-membrane vesicles (autophagic vacuoles), which later fuse
with lysosomes28. Chemical modulation of macroautophagy29–32
and genetic manipulation of essential macroautophagy genes32,33
change cellular tau levels. Interestingly, multiple lines of evidence
link defective macroautophagy with AD34–36.
Our own in vitro studies support that tau can also undergo
degradation via chaperone-mediated autophagy (CMA), a type of
selective autophagy that encompasses direct transport of substrate
proteins across the lysosomal membrane37. Selectivity of CMA is
conferred by the ability of the heat shock cognate protein of 70
kDa (hsc70) to recognize a pentapeptide motif38 (biochemically
related to the pentapeptide KFERQ) in CMA substrate proteins,
and deliver them to the lysosomal surface for binding to the
lysosome-associated membrane protein type 2A (L2A)39,40. Once
substrates bind, L2A multimerizes into a translocation complex41,
which allows access of substrate proteins into the lysosomal
lumen one-by-one. Substrate entry requires a form of hsc70
residing inside lysosomes, that completes substrate
translocation42. We have shown that tau contains several
KFERQ-like motifs, necessary for its lysosomal translocation into
lysosomes via CMA in vitro29.
Interestingly, the same pentapeptide recognized by hsc70 is
also utilized by this cytosolic chaperone to deliver cytosolic
proteins for degradation in late endosomes through endosomal
microautophagy (e-MI)43. In e-MI, the late endosome membrane
invaginates sequestering the hsc70/substrate complex into small
microvesicles that are then degraded in the endosomal lumen43.
Previous studies support that CMA and e-MI actively contribute
to the clearance of soluble forms of tau in cultured cells32. In
contrast, disease-related and phosphorylation-mimetic variants
display, in many instances, low rates of degradation through these
two types of selective autophagy, and in fact, they often exert an
2

inhibitory effect on them32. However, the repercussion of acetylation of tau on its degradation through CMA and e-MI remains
unknown.
In this study, we have analyzed the impact of acetylation on the
degradation of tau by these three different autophagic pathways
and found that acetylation reduces tau degradation through
CMA. Although macroautophagy degrades this form of the
protein with higher efﬁciency than the unmodiﬁed tau, the
association of acetylated tau with lysosomes renders them inactive
for CMA. We observed that this inhibition of CMA increases
extracellular tau release and that tau spreading was enhanced in
CMA-deﬁcient mice. We demonstrate experimentally that tau
release upon CMA blockage is a result of its rerouting to late
endosomes via e-MI. We propose that the toxic effect of acetylated tau on CMA described in this study could be responsible for
the CMA dysfunctions observed in brains from AD patients and
contribute to disease propagation, as demonstrated here in a
mouse model of tauopathy. These ﬁndings on the mechanisms
underlying autophagic clearance and cell-to-cell propagation of
tau could guide future therapeutic interventions in tauopathies.
Results
Acetylated tau is degraded by macroautophagy. To analyze the
impact of tau acetylation on its degradation by autophagy in vivo,
we ﬁrst measured changes in levels of total and acetylated tau in
different mouse brain regions upon blockage of all types of
lysosomal degradation with a combination of ammonium chloride and leupeptin. As previously described in cultured cells32, we
found that part of cellular tau was degraded in lysosomes, but that
inhibition of macroautophagy with the PI3Kinase inhibitor 3methyladenine (3MA) only prevented degradation of a fraction
(about 37–49% depending on brain region) of tau protein
(Fig. 1a). In contrast, acetylated tau at K174, which also displayed
lysosomal degradation, was mostly degraded via macroautophagy
(up to 80% of lysosomal degradation was prevented by 3MA)
(Fig. 1a). Controls for the selectivity of the acetylated antibody
using brains from tau knockout mice and of the efﬁciency of the
inhibitors are shown in Supplemental Fig. 1a, b. In further support of preferential degradation of acetylated tau by macroautophagy, analysis of brains from mice with compromised
macroautophagy (ATG7 knockout) revealed a signiﬁcant accumulation of acetylated tau (Fig. 1b, c). Using the same combination of inhibitors of lysosomal proteolysis as above, we
conﬁrmed that lysosomal degradation of acetylated tau was
severely compromised in brains from ATG7KO mice when
compared to wild type littermates (Fig. 1d, e), whereas lysosomal
degradation of unmodiﬁed tau protein was still observed in
macroautophagy-deﬁcient brains (Fig. 1b, e and Supplemental
Fig. 1d; note: the unexpected increase in total tau levels observed
upon 3MA treatment in the cortex of ATG7KO mice cannot be
due to changes in tau degradation by macroautophagy since this
pathway is blocked in these animals, and it likely results from
non-speciﬁc effects of PI3Kinase inhibition in these mice).
Differences in tau clearance can be directly attributed to the
acetylation of the protein since we could reproduce them using
ﬂag-tagged wild-type (WT) and an acetylation-mimetic form of
tau (mutation of lysine 274 and 281 to glutamine; KQ tau)
expressed at comparable levels in mouse embryonic ﬁbroblasts
(MEFs) (Supplemental Fig. 1e). As in the mouse brains, WT tau
was degraded primarily in lysosomes through a pathway
insensitive to 3MA, but the degradation of the acetylationmimetic form of tau occurred via macroautophagy and to a lesser
extent the proteasome (as reﬂected by sensitivity to the
proteasome inhibitor) (Supplemental Fig. 1f; efﬁciency of the
inhibitors is shown in Supplemental Fig. 1g).
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Two additional pieces of evidence supported the proposed
preferential degradation of acetylated tau through macroautophagy. First, we observed an increase in macroautophagy activity
in cultured cells upon expression of the acetylation-mimetic form
of tau (Supplemental Fig. 1h). Macroautophagy was monitored by
transducing cells with the tandem reporter mCherry-GFP-LC344
to quantify the number of autophagosomes (puncta positive for
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both ﬂuorophores) and maturation of autophagosomes into
autolysosomes (mCherry-only positive puncta due to quenching
of GFP ﬂuorescence at the low pH upon fusion with lysosomes).
We found that expression of KQ tau led to a signiﬁcant increase
in basal and in serum-removal induced macroautophagic ﬂux
compared to WT tau (Fig. 1f, g). This increase in macroautophagy in response to elevated levels of acetylated tau could be
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Fig. 1 Acetylated tau is degraded by macroautophagy. a Brain slices from the mouse cortex or midbrain were incubated in the presence or absence of
NH4Cl 20 mM and leupeptin 200 µM (N/L) or 3-methyladenine (3MA) 10 mM for 4 h at 37 °C and blotted for the indicated proteins. Right: Quantiﬁcation
of total tau (left) [Degradation pathway effect: F(2,78) = 14.31, p < 0.0001], acetylated tau (Ac-Tau; middle) [Degradation pathway effect: F(2,78) = 12.22, p
< 0.0001], and fraction of tau degraded by macroautophagy (MA) [Tau status effect: F(1,52) = 507.2, p < 0.0001], n = 15 (for cortex) and 13 (for midbrain)
mice per genotype. Controls of the selectivity of the acetylated antibody using brains from tau knockout mice and of the efﬁciency of the inhibitors are
shown in Supplemental Fig. 1a, b. b–e Brain slices from wild-type (WT) and Atg7 knockout mice (ATG7KO) cortex or midbrain were incubated as in a and
blotted for the indicated proteins. b Representative immunoblots. c Quantiﬁcation of total and acetylated tau in two brain regions (cortex and midbrain)
[Genotype effect: F(1,28) = 174, p < 0.0001]. d Changes of acetylated tau levels in both mice groups in the cortex (left) [Combined effect: F(2,42) = 4.280,
p = 0.0203] and midbrain (right) [Degradation pathway effect: F(2,42) = 3.707, p = 0.0329], n = 3. Changes in total tau are shown in Supplemental Fig. 1d.
e Flux of total and acetylated tau in the cortex (left) and midbrain (right) calculated as the fold increase in tau levels upon addition of N/L. f High content
microscopy representative images of a mouse neuroblastoma cell line Neuro-2a (N2a) transduced with mCherry-GFP-LC3 and transfected with
unmodiﬁed FLAG-wild-type Tau (WT) or acetylation-mimetic FLAG-K274,281Q tau (KQ) and maintained in the presence or absence of serum for 4 h.
Nuclei are highlighted with DAPI in blue. Insets show higher magniﬁcation images of the two channels. n > 800 cells/condition in three different wells
per day from cells transfected in 4 different days. g Quantiﬁcation of total autophagic vacuoles (AV), autophagosomes (APG, yellow puncta), and
autolysosomes (AUTL, red only puncta). n > 800 cells/condition in three different wells per day from cells transfected in 4 different days. Expression levels
of both proteins upon transfection in N2a cells are shown in Supplemental Fig. 1h. [Serum+: Tau status effect: F(2,18) = 49.37, p < 0.0001; Serum−: Tau
status effect: F(2,18) = 11.26, p = 0.0007] (h) Homogenate (HOM), Cytosol (CYT), Autophagosomes (APG), and Autolysosomes (AUT) were isolated from
mouse brain and blotted for the indicated proteins. Representative immunoblot. n = 3 mice. i Quantiﬁcation of enrichment (left) [Tau status effect: F(1,10) =
16.90, p = 0.0021] and recovery (right) [Tau status effect: F(1,10) = 16.92, p = 0.0021] of total tau and acetylated tau in the indicated fractions, n = 3 mice.
All values are mean ± s.e.m. Statistical analysis were done using Two-way ANOVAs (panels a, c, d, g, and i) and two-tailed t-tests or Wilcoxon tests
(panels e). Differences were signiﬁcant with untreated or WT tau for *p < 0.05, **p < 0.01, ***p < 0.005. For clarity purposes, only relevant statistical
comparisons are presented. Uncropped blots are shown in Supplemental Fig. 7.

elicited to facilitate its elimination through this pathway. In
agreement with this hypothesis, analysis of the forms of tau
detected in autophagosomes and autolysosomes isolated from
wild-type mice brains revealed signiﬁcantly higher enrichment of
acetylated tau in these fractions (folds increase of acetylated tau
per microgram of protein in the fractions relative to the
homogenate) when compared with total or phosphorylated forms
of tau (Fig. 1h, i and Supplemental Fig. 1i). In fact, the percentage
of cellular acetylated tau recovered in autophagosomes (recovery)
at a given time is almost double that of total tau (Fig. 1h, i),
further supporting that acetylated tau is actively targeted to these
autophagic compartments. Overall, these ﬁndings support that
acetylated forms of tau are preferentially degraded in the
lysosomal system via macroautophagy.
Reduced CMA contributes to the accumulation of acetylated
tau. Although most acetylated tau was undergoing degradation
via macroautophagy, analysis of brains from mice with speciﬁc
CMA blockage in pyramidal neurons (CKL2AKO) (Supplemental
Fig. 2a) revealed an increase in both unmodiﬁed and acetylated
tau (Fig. 2a; controls are shown in Supplemental Fig. 2b). Since
we have previously shown that macroautophagy is fully functional in CKL2AKO mice, it was more likely that the accumulation of acetylated tau was related to changes in tau itself, which
motivated us to analyze the interplay of acetylated tau and CMA
in more detail.
Using mouse brains to isolate subpopulations of lysosomes with
different CMA activity45 (organelle markers are shown in
Supplemental Fig. 2c), we conﬁrmed in vivo our earlier ﬁndings
that a fraction of cellular tau undergoes degradation via CMA29,32
and consequently can be detected preferentially in the lysosomes
with higher activity for this pathway (higher content of hsc70 in
their lumen) (Fig. 2b, bottom left graph). In contrast, the amount
of tau in lysosomes isolated from L2AKO brains was markedly
reduced (Fig. 2b, note that although the abundance of tau in
L2AKO brains was double than in wild-type littermates (bottom
middle graph), the amount of total tau recovered in lysosomes
from L2AKO mice was almost half than that in lysosomes from
wild-type mice (bottom right graph)). The observed changes in
lysosomal tau were not due to changes in the overall abundance of
lysosomes in L2AKO mice, which were comparable in number to
4

those in wild-type mice (Supplemental Fig. 2d). Using antibodies
speciﬁc for tau acetylated on different residues, we found that
some of the acetylated variants (i.e., acetylation on K174) were
detected in more abundance in CMA-active lysosomes, but that in
contrast with total tau, blockage of CMA did not reduce their
levels in these lysosomes (Fig. 2b, bottom right graph), in support
of tau association with the lysosomal surface without internalization. In agreement with our previously detected degradation of
acetylated tau by macroautophagy (Fig. 1), other acetylated forms
of tau (i.e., acetylation on K274) were detected in similar amounts
within CMA lysosomes and the group of lysosomes usually
engaged in macroautophagy (CMA-)46 (Fig. 2b).
The increase in total levels of acetylated tau upon CMA
blockage in vivo and the preferential association of some
acetylated forms of tau with lysosomes active for CMA led us
to directly analyze the translocation of acetylated tau inside
lysosomes via CMA. We acetylated puriﬁed tau (multi-acetylation
was conﬁrmed with antibodies speciﬁc for different tau acetylation sites, Supplemental Fig. 2e) and presented both acetylated
and non-acetylated tau to isolated intact lysosomes in a wellestablished in vitro system that allows recapitulating binding and
translocation of CMA substrates inside lysosomes47. Binding is
quantiﬁed as the amount of tau associated with lysosomes at the
end of the incubation (because the one internalized is rapidly
degraded), and uptake is the difference between binding and the
amount of tau associated with lysosomes pretreated with protease
inhibitors (to prevent degradation of the internalized tau).
Unmodiﬁed tau was rapidly internalized and degraded in
lysosomes (as it could only be detected in lysosomes pre-treated
with protease inhibitors), whereas acetylated tau remained for the
most part associated with the membrane and failed to translocate
(Fig. 2c, d). We conﬁrmed the absence of any proteasome
contamination in the isolated lysosomes that could account for
tau degradation (Supplemental Fig. 2f), and demonstrated that
uptake of unmodiﬁed tau was through CMA as it could be
outcompeted by the addition of GAPDH, a well-known CMA
substrate48 (Fig. 2e, g). In contrast, the addition of GAPDH did
not reduce the amount of acetylated tau associated with
lysosomes, and instead, we observed the gradual formation of a
high molecular weight complex of acetylated tau with some of
them remaining in the stacking of the gel (Fig. 2f–h). These
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results support that acetylation of tau markedly reduces its
degradation through CMA and that the reduced dynamics of
translocation may facilitate the irreversible formation of larger
molecular weight complexes of acetylated tau at the lysosomal
membrane, which could further compromise substrate uptake in
these organelles.
Acetylated tau reduces CMA activity. We have recently shown
that pathogenic tau mutants that fail to undergo degradation by
CMA persist associated with the lysosomal membrane and
interfere with the degradation of other proteins through this
pathway32. To determine if the acetylated tau that we found
persistently associated with the lysosomal membrane could also
be toxic for CMA, we analyzed CMA activity in cells expressing

ARTICLE

WT or the acetylation-mimetic form of tau (control of tau
expression is shown in Supplemental Fig. 3a). We monitored
CMA in cultured cells using photoswitchable Dendra ﬂuorescent
protein-tagged with the CMA-targeting motif (KFERQ-PSDendra49) that upon CMA activation relocalizes from the cytosol
to the surface of lysosomes giving a punctate ﬂuorescent pattern.
Transfection of neuroblastoma cells stably expressing the CMA
reporter with WT tau increased the number of ﬂuorescent puncta
and this increase was signiﬁcantly more accentuated in cells
expressing KQ tau (Fig. 3a, b). KFERQ-PS-Dendra protein only
preserves its ﬂuorescence while bound to the cytosolic side of the
lysosomal membrane but stops ﬂuorescing once internalized due
to its unfolding during translocation49. Consequently, to validate
whether the augmented association of CMA substrates with
lysosomes in cells expressing the tau proteins resulted in
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Fig. 2 Acetylated tau associates with CMA-active lysosomes. a Immunoﬂuorescence staining for tau and acetylated tau (Ac-Tau) of brain sections from
wild-type (WT) and CaMKinaseIIα-Cre-L2A knockout mice (L2AKO). n = 3 mice. b Immunoblot for the indicated proteins of homogenate (Hom), Cytosol
(Cyt), and two lysosomal (Lys) populations with different CMA activity (CMA+ and CMA−) isolated from WT and L2AKO mice brains. Bottom left plot:
Quantiﬁcation of the percentage of total tau recovered in the indicated fractions. [Two-tailed t-test t4 = 3.079, p = 0.037]. Bottom middle plot:
Quantiﬁcation of tau levels in L2AKO mice brain homogenate relative to WT (dotted line) [Two-way ANOVA Tau status effect: F(1,12) = 90.17, p < 0.0001].
Bottom, right plot: Quantiﬁcation of recovery of tau levels in lysosomes from L2AKO mice brain relative to WT [One-way ANOVA interaction effect: F(2,6) =
4.58, p = 0.061; Total vs. K274 p = 0.041] n = 3 mice. c Immunoblots of isolated lysosomes pretreated or not with protease inhibitors (PI) and incubated
with increasing concentrations of tau untreated (Tau) or acetylated in vitro (Ac-Tau). d Binding and uptake of tau calculated from quantiﬁcation of
immunoblots as the ones shown in c [Two-way ANOVA interaction effect: F(1,13) = 49.67, p < 0.0001], n = 3 independent experiments. e, f Effect of
increasing concentrations of glyceraldehyde 3-phoshpate dehydrogenase (GAPDH) in the association of tau (e) and Ac-Tau (f) with isolated liver lysosomes
pre-incubated or not with protease inhibitors (PI) as labeled. The dashed line indicates the separation between running and stacking. n = 3 independent
experiments per type of tau and amount of GAPDH. g Quantiﬁcation of the effect of increasing concentrations of GAPDH on binding [Two way ANOVA Tau
status effect: F(1,12) = 6.033, p = 0.0302] and uptake [Two-way ANOVA Tau status effect: F(1,12) = 5.815, p = 0.0328] of control and acetylated tau (note
that acetylated includes all variants independently of their molecular weight). n = 3 independent experiments. h Quantiﬁcation of the percentage of
lysosome-associated acetylated tau detected as monomer, dimer, or higher molecular weight (HMW) complexes in the stacking of the gel upon addition of
GAPDH. n = 3 independent experiments [Two-way ANOVA interaction effect: F(4,18) = 4.894, p = 0.0076]. All values are mean ± s.e.m. Differences with
unmodiﬁed tau were signiﬁcant for *p < 0.05 05, **p < 0.01, ***p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.

increased translocation and degradation, we measured the rates of
degradation of long-lived proteins, typical autophagy substrates,
under the same conditions. Contrary to the CMA reporter data,
we found that total protein degradation rates were signiﬁcantly
reduced upon expression of the acetylation-mimetic form of tau
and that this decrease was even more pronounced when only the
3MA-insensitive lysosomal proteolysis (no macroautophagy) was
accounted for (Fig. 3c). These results suggest that an increase in
the cellular levels of acetylated tau leads to reduced rates of CMA
and that this blockage does not interfere with substrate binding
with the lysosomal surface, but it mainly affects substrate translocation inside lysosomes.
To further elucidate the mechanism behind the observed CMA
blockage by acetylated tau, we analyzed the lysosomal translocation complex that forms by oligomerization of L2A41 and can be
detected as a 700 kDa complex after subjecting lysosomes to bluenative electrophoresis and immunoblot for L2A50. This complex
is rapidly disassembled into L2A monomers as soon as
translocation is completed to allow for a new cycle of binding/
translocation41. We found a signiﬁcant increase in the amount of
L2A organized into translocation complexes upon exposure of
lysosomes to acetylated tau that was not detected when using
unmodiﬁed tau (Fig. 3d and Supplemental Fig. 3b). We
considered the possibility that acetylated tau primarily inhibited
L2A disassembly leading to an abnormally higher number of
translocation complexes. However, disassembly of L2A in the
presence of acetylated tau could still be forced by adding an
excess of cytosolic hsc70 (previously shown to contribute to the
dissociation of L2A from the multimeric complex41) (Fig. 3e) or
with chemical activators of hsc7051 (Supplemental Fig. 3b).
Next, we investigated possible changes in the other components that contribute to substrate translocation, namely hsc70
present at the cytosolic and in the luminal side of the lysosomal
membrane39,42,45,52. Incubation of the tau proteins with recombinant GST-hsc70 revealed lower binding of acetylated tau to
hsc70 as compared to unmodiﬁed tau (Fig. 3f). Because the
luminal lysosomal resident hsc70 completes translocation of
substrates by binding to them as they enter the lysosomal acidic
environment42, we tested the effect of acidiﬁcation on the tau/
hsc70 binding and found a very pronounced increase in binding
between both proteins as pH decreases (Fig. 3g). These pHdependent differences in afﬁnity for hsc70 provide a possible
explanation for the unusual rapid translocation of tau into
lysosomes when compared to other CMA substrates. Interestingly, binding between hsc70 and acetylated tau did not increase
at lower pH, and instead, acidiﬁcation seemed to further reduce
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both proteins’ interaction (Fig. 3g). We conﬁrmed the pH
dependence of hsc70 and tau binding, with tighter binding at pH5
than pH8, using a quantitative ELISA-based binding assay with
immobilized hsc70 (Fig. 3h, top and Supplemental Fig. 3c).
Comparison of binding of unmodiﬁed and KQ tau in the same
assay revealed lower binding afﬁnity of hsc70 for the acetylationmimetic tau protein more evident at low pH (dissociation
constants at pH 5 of 0.78 and 5.91 for WT and KQ tau,
respectively) (Fig. 3h, i and Supplemental Fig. 3d). In fact, when
comparing the binding of KQ tau to hsc70 at different pH, the
enhanced binding at low pH, observed for control tau, was no
longer evident for the modiﬁed tau protein (Fig. 3h, bottom).
To functionally validate that stronger hsc70/tau binding at low
pH was required for efﬁcient lysosomal translocation of tau, we
analyzed the effect of dissipating lysosomal pH on tau translocation. Neutralization of the lysosomal pH by incubation with
ammonium chloride did not affect lysosomal membrane stability
(Supplemental Fig. 3e) or the ability to translocate other CMA
substrates into lysosomes (GAPDH shown in Supplemental
Fig. 3f). However, translocation of tau was markedly reduced
when the pH gradient across the lysosomal membrane was no
longer present, further supporting that the unusually fast
translocation of tau into lysosomes is dependent on its higher
binding afﬁnity with hsc70 at low pH (Fig. 3j,k). Neutralization of
the lysosomal pH did not signiﬁcantly affect the already low
lysosomal translocation of acetylated tau (Fig. 3j,k). Overall, these
results suggest that the fast translocation of tau into lysosomes via
CMA relies heavily on the pH-sensitivity of hsc70/tau binding
and that acetylation of tau reduces the efﬁciency of its lysosomal
translocation, at least in part, because of the loss of this pH
sensitivity for hsc70 binding.
Tau rerouting to e-MI contributes to its extracellular release.
Hsc70 also mediates selective degradation of cytosolic proteins in
late endosomes through endosomal microautophagy (e-MI)43. In
light of the negative impact of tau acetylation on its degradation
by CMA and our recent ﬁndings that a fraction of unmodiﬁed tau
undergoes e-MI degradation32, we investigated whether acetylation affected the degradation of tau through e-MI. We ﬁrst presented the puriﬁed tau proteins to isolated late endosomes/
multivesicular bodies (LE/MVB) from tau-null mice brains
incubated or not with protease inhibitors to assess the association
and degradation of exogenously added tau in these compartments. We found that unmodiﬁed tau was binding to and taken
up by LE/MVB and that this process was even more efﬁcient for
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acetylated tau (Fig. 4a, b). Interestingly, in the case of acetylated
tau, not only the monomer but also high molecular weight forms
of the protein could be detected in LE/MVB but only when
proteolysis was prevented (Fig. 4a, b), in agreement with the
previously described ability of e-MI to internalize and degrade
fully folded proteins even when organized into oligomeric
complexes53.

Ac-Tau

Immunoblot of mouse brain LE/MVB for tau conﬁrmed that a
fraction of the endogenous protein was detectable in these
compartments both as monomer and as high molecular weight
protein complexes retained for the most part in the stacking of
the gel (Fig. 4c). Using the antibodies speciﬁc for acetylation of
tau at different lysine residues, we found that some of the
acetylation variants, but not phosphorylated tau, were highly
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Fig. 3 Acetylated tau has an inhibitory effect on CMA activity. a Representative images of mouse neuroblastoma cell line Neuro-2a (N2a) transduced
with KFERQ-PS-Dendra2 and transfected with empty vector (Control), FLAG-wild-type tau (WT Tau) or FLAG-K274,281Q tau (KQ Tau), and maintained in
the presence (+) or absence (−) of serum for 16 h. Nuclei are highlighted with DAPI in blue. Insets show higher magniﬁcation images and arrows point
examples of ﬂuorescent puncta. n > 800 cells/condition in three different wells and 4 independent experiments. b Quantiﬁcation of an average number of
puncta per cell section. [Two-way ANOVA Tau status effect: F(2,12) = 179.1, p < 0.0001], n > 800 cells/condition in three different wells, and n = 4
independent experiments. Controls for tau expression are shown in Supplemental Fig. 1h (protein levels) and Supplemental Fig. 3a (mRNA levels).
c Degradation rates of long-lived proteins in N2a cells transfected as in a and radiolabeled for 48 h with 3H-leucine), [One-way ANOVA Tau status effect:
F(2,6) = 4;619, p = 0.0610]. Right: fraction of degradation occurring in lysosomes (sensitive to inhibition of lysosomal proteolysis), [One-way ANOVA Tau
status effect: F(2,6) = 14.55, p = 0.005], n = 3 independent experiments. d Immunoblot for L2A of isolated lysosomes subjected to blue-native
electrophoresis after being incubated alone (No protein) or with unmodiﬁed (Tau) or in vitro acetylated tau (Ac-Tau). A 700-kDa multimeric complex and
the 110-kDa monomer are shown. Right: Quantiﬁcation of multimeric levels of L2A relative to those in lysosomes incubated alone. [One-way ANOVA Tau
status effect: F(2,13) = 5.580, p = 0.0178], n = 4 independent experiments. e Lysosomes incubated and processed under the same conditions as in d but
in the presence or absence of hsc70. f Immunoblot for tau of the GST-pulldowns of GST-hsc70 incubated with tau or Ac-Tau at neutral pH for 30 min at
37 °C. Input (Ipt): 1/10 of tau added to the incubation. Right: Quantiﬁcation of tau bound to Hsc70. [Two-tailed t-test t4 = 4.432, p = 0.0114], n = 3.
g Samples incubated as in f but at different pH. Right: Quantiﬁcation of tau bound to hsc70 [Two-way ANOVA Tau status effect: F(1,18) = 10.85, p =
0.0040], n = 4 independent experiments. h Tau or K280Q tau binding assay to immobilized hsc70 determined by ELISA at the indicated pH. See also
Supplemental Fig. 3b and c for binding assays at intermediate pH. n = 6 (in 2 independent experiments). i Summary plot of the binding assay at all
tested pH for tau and acetylated tau (Ac-Tau). [Two-way ANOVA Tau status effect: F(1,8) = 42.10, p = 0.0002]. n = 6 (in 2 independent experiments).
j Immunoblots of lysosomes from starved rat livers, pretreated or not with protease inhibitors (PI) and/or NH4Cl 20 mM for 10 min at 4 °C and then
incubated with tau (left) or Ac-Tau (middle). n = 3 independent experiments. k Quantiﬁcation of tau proteins binding and uptake by lysosomes. [Two-way
ANOVA Tau status effect: F(1,17) = 17.22, p = 0.0013], n = 3 independent experiments. All values are mean ± s.e.m. Differences with control or unmodiﬁed
tau were signiﬁcant for *p < 0.05, **p < 0.01, ***p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.

enriched in LE/MVB either as monomers and/or as high
molecular weight protein complexes (Fig. 4c and Supplemental
Fig. 4a). These results suggest that even in the brains of young
healthy mice, a fraction of acetylated tau organizes into
irreversible high molecular weight protein complexes that seem
to be cleared from the cytosol via e-MI. Interestingly, the amount
of high molecular weight forms of acetylated tau reaching LE/
MVB markedly increased in the brains of mice with compromised CMA (L2AKO mice) (Fig. 4d) making us hypothesize that
e-MI could be a rerouting mechanism for the acetylated tau that
oligomerized upon CMA blockage.
To gain a better understanding of the consequences of tau
rerouting to LE/MVB and to conﬁrm that delivery of tau to LE
used conventional e-MI mechanisms, we knocked down Vps4—
one of the components of the endosomal sorting complexes
required for transport previously shown necessary for e-MI43—in
cells expressing tau. Knock-down of Vps4 led to increased cellular
levels of tau, reduced tau degradation, and resulted in a decrease
in the discrete amount of tau detected in the extracellular
media in these cells (Supplemental Fig. 4b). Since LE/MVB can
fuse with the plasma membrane and release their content
extracellularly54,55, we contemplated the possibility that the
presence of tau in LE/MVB could be a route for extracellular
release. In fact, we noticed that CSF from L2AKO mice contained
a higher abundance of tau compared to wild-type littermates and
that a large fraction of this extracellular tau was acetylated
(Fig. 4e), coinciding with our observation of increased content of
acetylated tau in LE/MVB from these mice (Fig. 4d). We found
that acetylated tau was also the form of the protein preferentially
detected in the extracellular media of iPSC-derived human
neurons upon induction of its release as previously described by
neuronal activation21 (Fig. 4f).
To directly test the contribution of changes in the degradation
pathway of tau to its extracellular release, we next used ELISA to
measure extracellular tau upon blockage of the different
autophagy pathways in N2a cells (Fig. 4g; Supplemental Fig. 4c).
Contrary to recent reports in other cell types supporting that
ESCRT machinery is required for macroautophagy56, knockdown of Vps4 in N2a cells did not reduce macroautophagy
activity in these cells (Supplemental Fig. 4d, e). In fact, upon
microautophagy blockage, we observed a consistent increase in
8

macroautophagy ﬂux and autolysosome number (Supplemental
Fig. 4d), likely of compensatory nature, since, despite increased
rates of macroautophagy-dependent degradation in Vps4 knockdown cells, overall proteolysis remained unchanged from control
cells (Supplemental Fig. 4e). The presence of fully functional
macroautophagy upon Vps4 knock-down made this intervention
suitable to assess the contribution of e-MI to tau secretion.
Blockage of e-MI (Vps4 knock-down) or macroautophagy (Atg7
knock-down) alone resulted in a modest but consistent decrease
in extracellular tau, whereas blockage of CMA led to a massive
increase in extracellular tau release (Fig. 4g), consistent with the
higher abundance of tau in CSF from L2AKO mice (Fig. 4e).
Interestingly, the release of extracellular tau upon CMA blockage
was completely prevented if we imposed e-MI blockage on CMAdeﬁcient cells (Fig. 4g). These ﬁndings are in agreement with our
proposed model of active rerouting of tau to e-MI upon CMA
blockage and its extracellular release from LE/MVB (Fig. 4g).
Altogether, these results show that e-MI also contributes to the
sequestration of acetylated tau, especially in the context of CMA
deﬁciency, and that the presence of tau in LE/MVB provides a
route for its active extracellular release.
CMA dynamics are altered in AD patient brains. Levels of
acetylated tau are elevated in post-mortem brain samples from
patients with various tauopathies7,8. To determine whether the
changes imposed by acetylated tau on autophagy in the in vitro
systems—namely, reduced CMA through disruption of lysosomal
L2A dynamics and rerouting of acetylated tau oligomers to e-MI—
were also observed in the brains of patients with Alzheimer’s
disease (AD), we isolated two populations of lysosomes with different CMA activity, LE/MVB and autophagosomes from brains of
6 patients with autopsy-conﬁrmed AD and 7 age-matched autopsy
conﬁrmed controls (no-AD) (patient information is summarized
in “Methods” section). AD diagnosis was also supported by the
marked differences in levels of hyperphosphorylated tau between
control and AD brains (Supplemental Fig. 5a). Analysis of the
different autophagic compartments (Supplemental Fig. 5b–d show
enrichment of relevant organelle markers) demonstrated acetylated
tau associated with lysosomes isolated from control individuals
and, similar to mouse brain lysosomes, a preferential enrichment
of this form of the protein in the group of lysosomes active for
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CMA (Fig. 5a). Interestingly, the pattern of lysosomal association
of acetylated tau in the human AD brains (Fig. 5a) remarkably
resembled the one observed in the brains of mice with compromised CMA (Fig. 2b), whereby, the preference for CMA-active
lysosomes is lost and acetylated tau redistributed evenly between
both subgroups of lysosomes, indirectly suggesting a possible
compromise of CMA in these patients.
The reduced levels of luminal hsc70 in the population of CMAactive lysosomes in AD (usually related to loss of stability of this
chaperone in the lysosomal lumen upon loss of lysosomal
acidiﬁcation45) (Fig. 5a), as well as the higher presence of
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undegraded cargo in lysosomes isolated from AD brains (Fig. 5b),
is in agreement with the reported loss of lysosomal acidiﬁcation in
some types of AD36,57. We hypothesized that the possible loss of
pH gradient in AD brain lysosomes, along with the presence of
acetylated tau protein at the lysosomal membrane (Fig. 5c and
Supplemental Fig. 5f, conﬁrms a 50% reduction in the amount of
acetylated tau that reaches the lysosomal lumen), could result in
similar interruption of lysosomal translocation of tau proteins and
persistence of L2A into multimeric complexes to the one observed
in the in vitro system (Fig. 3d). In fact, we found that despite their
similar levels of L2A (Fig. 5a), a signiﬁcantly larger fraction of this
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Fig. 4 Acetylated tau and endosomal microautophagy. a Immunoblots of late endosomes (LE) isolated from tau-null mice brains, pretreated or not with
protease inhibitors (PI), and incubated with tau or in vitro acetylated tau (Ac-tau). Tau input is 1/5 of the protein added. b Quantiﬁcation of endosomal
binding [Two-tailed t-test t7 = 13.80, p < 0.0001] and uptake [Two-tailed t-test t7 = 3.239, p = 0.0143] of tau proteins from blots as in a. n = 3 mice. c
Immunoblot with the indicated antibodies of homogenate (Hom) and late endosomes (LE) isolated from mice brain. A dashed line indicates the separation
between running and stacking in the gel. The same homogenate and LE fractions were loaded in triplicate in a membrane and strips of the membrane were
separately incubated with each of the antibodies to allow for comparison among antibodies. d Immunoblot for the indicated antibodies of Hom, cytosol
(Cyt), and LE isolated from brains of wild-type (WT) and L2A knock-out mice (L2A KO). Dashed lines as in c. Right: quantiﬁcation of the amount of total
and acetylated tau in monomer [Two-way ANOVA genotype effect: F(1,8) = 10.56, p = 0.0117] and in high molecular weight (HMW) complexes [Twotailed t-test t4 = 2.694, p = 0.0545]. n = 4 mice. e Immunoblot for total and acetylated tau in CSF isolated from wild-type and L2AKO mice. n = 3 mice per
genotype were pooled for each immunoblot; the 2 samples shown here correspond to isolations done in 2 separate days. f Immunoblot for the indicated
forms of tau of lysates and culture media from iPSC-derived human neurons upon stimulation with KCl for 30 min. Note: saturated bands are shown for
the lysates in the PHF-1 membrane to illustrate the small amount of phosphorylated tau detected in the media. n = 4 different experiments performed in
2 different iPSC cell lines. g Left: Scheme illustrating rerouting of tau towards LE/MVB upon blockage of CMA and extracellular release of tau after fusion of
LE/MVB with the plasma membrane. APG: autophagosome, Lys: lysosome. Right: Quantiﬁcation of extracellular tau using ELISA upon blockage of the
various autophagy pathways in N2a cells expressing human P301LTau. Vps4: VPS4 knock-down, L2A: L2A knock-down, Atg7: ATG7 knock-down, L2A +
Vps4: a combination of L2A and VPS4 knock-down. The efﬁciency of the different knock-downs is shown in Supplemental Fig. 4c. Values are expressed as
the fold on PGK (Control). [One-way ANOVA F(4,37) = 9.542, p < 0.0001]. n = 8, 10, 9, 9, 6 (in order of genotype shown in the graph) independent
experiments. All values are mean ± s.e.m. Differences with control or unmodiﬁed tau were signiﬁcant for *p < 0.05, **p < 0.005. Uncropped blots are shown
in Supplemental Fig. 7.

protein remained organized into multimeric complexes in the
human AD brain lysosomes (Fig. 5d, e). While lysosomes from
control brains exposed to a CMA substrate (α-synuclein shown
here) display an increase in the multimeric levels of L2A to
facilitate substrate uptake, levels of multimeric L2A in AD patient
lysosomes exposed to the CMA substrate fail to increase and even
decrease in some AD brains (Fig. 5d, f), further supporting altered
dynamics of L2A. Our ﬁndings support deﬁcient functioning of
CMA in AD patients due to the inability of L2A to go through
normal rounds of assembly and disassembly.
Autophagic vacuoles isolated from AD brains (Fig. 5g, h, and
Supplemental Fig. 5c) displayed higher content of acetylated tau
(1.6 folds) than those from control brains, reﬂecting in part the
overall cellular increase in acetylated tau and in agreement with
the preferential degradation of this form of the protein by
macroautophagy observed in vitro and in mouse brain sections
(Fig. 1). Interestingly, while the ratio of acetylated to total tau in
AD autophagic vacuoles was comparable between control and
AD, in support of higher overall entrapment of tau by
autophagosomes, we noticed a marked shift to an increase in
the fraction of acetylated tau in the LE/MVB isolated from AD
brains (Fig. 5g, i and Supplemental Fig. 5d). Almost all of the
acetylated tau in AD LE/MVB was in the form of irreversible
higher molecular weight protein complexes (Fig. 5g, j), strikingly
resembling those observed in brains of CMA-incompetent mice
(L2AKO) (Fig. 4d). Immunoblot with a speciﬁc antibody against
oligomers of human tau conﬁrmed the oligomeric nature of the
protein trapped in LE/MVB and higher abundance of oligomers
in LE/MVB from AD brains (Supplemental Fig. 5g). The LE/
MVB-associated oligomeric complexes were in contrast barely
detectable with the antibody against total tau, in further support
of a preferential entrapment of only acetylated tau proteins
(Fig. 5g and Supplemental Fig. 5e). These results demonstrate the
conservation of the molecular signature of the autophagic defects,
observed in vitro and in the experimental models, in the AD
brain, and support the occurrence of acetylated tau rerouting to
LE/MVB in AD patients’ brains. Such rerouting could provide a
mechanistic hypothesis for extracellular tau release supporting
the cell-to-cell propagation of tau.

ﬂuorescent protein (GFP)-2a-human tau (huTau)58,59 that generates equimolar amounts of GFP and human tau upon selfcleavage. Following unilateral injection in CA1, we could identify,
by immunoﬂuorescence, transduced neurons (donor cells [GFP
+/huTau+]) and neurons that received huTau through cell-to-cell
propagation (recipient cells [GFP−/huTau+] (Fig. 6a). Transduction was mostly neuronal as no huTau signal was observed
colocalizing with astrocytes or microglia markers (Supplemental
Fig. 6a). Recipient neurons were observed throughout the hippocampal formation suggesting a mixed synaptic and nonsynaptic (global) transmission of tau59.
When we injected WT and CMA-deﬁcient (L2AKO) mice and
collected brain tissue after 2, 4, and 8 weeks following injection
(Fig. 6b and Supplemental Fig. 6b, c), we observed a strong
accumulation of huTau (1.6 folds) compared to GFP (1.1 folds) in
L2AKO mice, thus conﬁrming the contribution of CMA to tau
clearance (Fig. 6c, d). Despite similar numbers of donor cells and
tau expression (Supplemental Fig. 6b, c), the number of recipient
cells was also signiﬁcantly higher in L2AKO mice compared to
WT mice, especially at the latest timepoint (Fig. 6e). In fact, the
correlation between the numbers of recipient neurons and donor
neurons in a given genotype showed a steeper slope (4.4 folds) in
L2AKO mice compared to WT mice (Fig. 6f), supporting those
donor neurons in L2AKO mice are more prone to spread. Direct
analysis of acetylated tau in the injected brains, showed
accumulation of acetylated tau in both donor and recipient
neurons in CMA-deﬁcient mice (Fig. 6g and Supplemental
Fig. 6d–f). Furthermore, we observed a strong relationship
between levels of acetylated tau in donor neurons and the
number of neurons that become positive for tau through
spreading (recipient neurons) (Fig. 6h), thus suggesting that
elevation of intracellular acetylated tau predicts tau propagation
in this mouse model of tauopathy.
Overall, our ﬁndings highlight a complex interplay of
acetylated tau with different autophagic pathways, reveal a toxic
effect of this modiﬁcation on CMA function with the possible
rerouting of acetylated tau towards other selective autophagy
pathways in disease brains, ultimately leading to enhanced
extracellular release and cell-to-cell propagation.

CMA deﬁciency accelerates tau spreading. To experimentally
test whether CMA deﬁciency, as the one observed in AD patients,
increases tau spreading in vivo, we took advantage of a recently
developed adeno-associated virus (AAV) expressing green

Discussion
In this study, we have characterized the contribution of CMA to
tau degradation in vivo and discovered how this process is
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severely blunted upon tau acetylation. Acetylated tau, under
normal conditions, is efﬁciently cleared up by macroautophagy,
but a fraction of acetylated tau targeted to CMA exerts an inhibitory effect on this selective type of autophagy. We show here
that CMA blockage favors rerouting of oligomers of acetylated
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tau toward LE/MVB by e-MI and that this mechanism could lead
to extracellular release and cell-to-cell propagation of tau.
Although the tau propagation studies in this work were performed in a mouse model of tauopathy, the fact that the same
molecular mechanisms behind the toxicity of acetylated tau on
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Fig. 5 Changes in the association of tau with autophagic and lysosomal compartments in Alzheimer’s disease patient brains. a Immunoblots for the
indicated proteins of homogenates (Hom), cytosol (Cyt), and two populations of lysosomes (Lys) with different CMA activity (CMA+ and CMA−)
isolated from the frontal area of brains from patients with Alzheimer’s Disease (AD, n = 6) and non-neurological patients of matching age (Control, n = 7).
b Pictures of CMA-active lysosomes isolated from control (n = 3) or AD (n = 3) patients’ brains and subjected to electron microscopy. Right: higher
magniﬁcation inserts. Red arrows: undegraded dense lipofuscin-like material. Differences noted in the images were reproducible in the 3 brains.
c Immunoblot for acetylated tau (Ac-Tau) in lysosomal matrices from control and AD patients. Right: Quantiﬁcation of the amount of acetylated tau
(Ac-Tau) internalized in AD patients’ lysosomes relative to control [Two-tailed t-test t4 = 6.831, p = 0.0024]. n = 3 samples (1 per brain) per group.
d Immunoblot from L2A of the blue-native electrophoresis of lysosomes isolated as in a and incubated alone (No substrate) or in the presence of 1 µg of
puriﬁed alpha-synuclein (Alpha syn). Two different individuals per diagnosis are shown. Multimer: indicates the 700-kDa multimeric translocation
complex. Monomer: insert of the monomer run in a different gel. n = 6 control and 6 AD patient brains. e Quantiﬁcation of multimeric L2A levels relative to
those in control lysosomes in absence of substrate [Two-tailed t-test t11 = 4.936, p = 0.0004]. n = 7 control and 6 AD patient brains. f Quantiﬁcation of
multimeric L2A levels in absence of substrate (N.S.) or upon substrate (α-syn) presentation. Top changes of multimeric L2A for individual subjects.
Bottom: Fold increase of L2A multimers upon substrate presentation [Two-tailed t-test t11 = 3.607, p = 0.0041]. n = 7 controls and 6 AD patient
brains. g Immunoblots for the indicated proteins of homogenates (Hom), cytosol (Cyt), autophagic vacuoles (AV), and late endosomes (LE) isolated
from patients with Alzheimer’s Disease (AD) and non-neurological patients of matching age (Control). n = 3 samples (1 per brain) per condition.
h Quantiﬁcation of the abundance of acetylated tau in autophagic vesicles [Two-tailed t-test t4 = 2.805, p = 0.0486]. n = 3 samples (1 per brain) per
group. I, j Quantiﬁcation of the ratio of acetylated to total tau in the indicated fraction (i) and of the abundance of the high molecular weight (HMW)
acetylated tau species in LE (j). [Two-tailed t-test t4 = 8.719, p = 0.001]. n = 3 samples (1 per brain) per group. All values are mean ± s.e.m. Differences
with control were signiﬁcant for *p < 0.05, **p < 0.01, ***p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.

CMA and the accumulation of oligomeric acetylated tau in LE/
MVB can be detected in brains from AD patients highlights CMA
disruption as a previously unknown common feature of the AD
brains that could also contribute to neuronal degeneration and
disease progression.
We identiﬁed a pH dependence for internalization into lysosomes via CMA, unique for tau, that explains its highly efﬁcient
degradation through CMA under normal conditions. So far, we
have not observed such a feature in any of the known CMA
substrates, but future studies will determine if pH-dependent
binding to hsc70 is a shared feature of a subset of CMA substrates. The mechanisms behind the toxic effect of acetylated tau
on CMA are also different from the one described before for
other neurodegeneration-related pathogenic proteins, such as
alpha-synuclein60 and leucine-rich repeat kinase 261. These proteins disrupt CMA by preventing the formation of the CMA
translocation complex. In contrast, assembly of the multimeric
L2A complex and translocation of pathogenic tau is initiated
normally, but it is halted by loss of the pH-dependent interaction
with hsc70. This result suggests that conditions that compromise
lysosomal acidiﬁcation, such as those described in familial
AD36,57 could also have a negative impact on the degradation of
tau by CMA. Therefore, restoring lysosomal acidiﬁcation could
help reinstate normal tau degradation by CMA, as long as the
CMA blockage is reversible. Our in vitro studies with chemical
hsc70 activators to enhance its disassembling effect on the L2A
multimeric complex41 support CMA blockage reversibility.
However, the efﬁciency of such types of approaches in the AD
brain after chronically sustained disruption of CMA by acetylated
tau could be different.
The combined analysis of unmodiﬁed tau degradation with
that of the acetylation-mimetic variants supports that acetylation
(K174 or K274) favors the degradation of tau through macroautophagy. Acetylated tau seems to be targeted to autophagosomes actively instead of through in bulk sequestration because
levels of acetylated tau are almost undetectable in the cytosol but
highly enriched in autophagosomes (Fig. 1f). Selective degradation of proteins by macroautophagy occurs often through
aggrephagy, which ﬁrst requires aggregation and subsequent
recognition by speciﬁc macroautophagy receptors. Selective targeting to macroautophagy upon acetylation has also been
described for huntingtin through promoting its organization into
large complexes recognized by the autophagy receptor p6262.
However, we did not detect the organization of acetylated tau in
12

aggregates or oligomers inside autophagosomes, suggesting that it
is not a prerequisite for its macroautophagy degradation. Future
studies are needed to identify the molecular components that
allow for selective macroautophagy of acetylated tau.
Although acetylated tau seems preferentially degraded through
macroautophagy in steady-state conditions, its accumulation in
L2AKO brains implies a role for CMA in regulating its intracellular levels. Since acetylation is dynamic and the fraction of
acetylated tau may be dependent on total tau levels, acetylation
could occur secondary to the CMA blockage and accumulation of
unmodiﬁed tau. In this context, a reduction in CMA activity as
the one described in aging may trigger the accumulation of the
forms of acetylated tau that we demonstrate to be toxic for CMA,
further perpetuating reduced CMA activity. It is also possible that
some acetylated forms of tau are targeted to CMA-active lysosomes. For example, the fact that K174 tau was more abundant in
CMA-active lysosomes and blockage of CMA increased its
abundance in macroautophagy-engaged lysosomes, supporting
possible rerouting of acetylated variants from one autophagic
pathway to another. Although we did not ﬁnd that K174 acetylation generated a CMA-targeting motif in tau by mimicking the
biochemical properties of glutamine, as described for other
substrates63, it is possible that acetylation of this residue alters tau
structure thus exposing its canonical CMA-targeting motifs29.
Interestingly, in contrast to the reduced degradation of acetylated tau by CMA, we found that this form of the protein was
more readily degraded by e-MI, even when in oligomeric form
since e-MI does not need substrate unfolding as a prerequisite43.
Rerouting to e-MI might allow acetylated tau to bypass the steps
that presented a challenge for its degradation through CMA,
making removal of an oligomeric complex of acetylated tau from
the cytosol more favorable. How hsc70 triages proteins for CMA
or e-MI is still poorly understood. However, K274 acetylation,
recently shown to increase tau interaction with hsc7064, showed
no preference for CMA-active lysosomes but a high enrichment
in LE/MVB, suggesting that post-translational modiﬁcations in
the substrates and/or their ability to unfold may determine
binding afﬁnity for hsc70 and the compartment where the chaperone targets them. Since the amount of acetylated tau in diseased brain is dynamic and would differ greatly in neurons at
different disease stages, future studies directly determining the
percentage of total tau acetylated at each stage should provide key
information to estimate the contribution of the observed rerouting of tau to LE/MVB in disease progression. In light of our
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ﬁndings showing that levels of speciﬁc acetylation on tau (i.e., acK174) also differ greatly in different subcellular compartments,
quantitative analysis of the percentage of acetylated tau will need
to be performed at the subcellular level.
Cell-to-cell propagation of tau is thought to underlie pathology
spreading in the brain, however, the mechanism(s) for tau
secretion is poorly understood65. We demonstrate that e-MI is
efﬁcient in the degradation of acetylated tau and that it also

allows its extracellular release. This dual function stems from the
fact that LE/MVB can degrade proteins directly or upon fusion
with lysosomes, but they can also fuse with the plasma membrane
and release their luminal content (exosomes)65. The small
amount of extracellular tau upon e-MI or MA blockage suggests
that these pathways contribute to tau release in basal
conditions23. Exacerbated release through LE/MVB is also the
mechanism behind the striking increase in extracellular tau
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Fig. 6 CMA deﬁciency accelerates Tau spreading. a Example of immunoﬂuorescence for human tau (huTau-red) and GFP (Green) of the whole
hippocampal formation in coronal section. Bottom pictures are representative pictures of donor [GFP+/huTau+] and recipient [GFP−/huTau+] cells.
Scale bars: top: 100 µm; bottom 20 µm. n = 20 mice (10 WT and 10 L2AKO). b Representative images of Tau and GFP levels in CA1 (injection site) and
CA3 (spreading site) in WT and L2AKO mice at 8 weeks after surgery. Scale bar: 50 µm. n = 4 mice per genotype. c Distribution of GFP intensity in donor
cells (with kernel density estimation) in WT and L2AKO mice. d Distribution of human Tau intensity in donor cells (with kernel density estimation) in WT
and L2AKO mice [Two-tailed t-test t553 = 16.113, p = 3.69 × 10−48]. e Number of recipient cells over time [Two-way ANOVA genotype effect: F(1,14) =
7.668, p = 0.0151]. n = 3, 3, and 4 mice per genotype at 2, 4, and 8 weeks, respectively. f Left: scatterplot showing the average number of recipient versus
donor cells per mouse. Dotted lines are the linear regression per genotype. Right: slopes of the linear regression between recipient and donor cells per
genotype. n = 3, 3, and 4 mice per genotype at 2, 4, and 8 weeks, respectively. h Scatterplot showing the average intensity of acetylated tau in donor cells
versus the average number of recipient cells per mouse. The dotted line is the mean linear regression +/−95% conﬁdence interval (gray zone). g Levels of
human tau (huTau) and K174 acetylated tau (ac-Tau) in recipient cells between WT and L2AKO mice. n = 4 mice per genotype. Scale bar: 50 µm. All
values are mean ± s.e.m. except otherwise speciﬁed. Differences with WT mice were signiﬁcant for *p < 0.05, ***p < 0.0005.

observed upon CMA blockage. Our data using the GFP-2a-huTau
construct conﬁrms that this increased secretion in CMA-deﬁcient
animals is accompanied by uptake in neighboring neurons and
acceleration of spreading in the brain. This observation makes
attractive the idea that the previously described decline of CMA
activity with age66 could be behind the recently described accelerated spreading of tau in aging59. Future studies are now
required to assess if tau propagation in the aging brain involves
rerouting of tau towards e-MI and if the spreading observed here
for P301L tau, a mutation associated with FTD but not AD67 is
also reproduced for other forms of tau.
The isolation of autophagy/lysosomal compartments from AD
patient brains performed in this work provides, for the ﬁrst time,
information on the forms of tau associated with each of the
compartments and the changes in this association with disease.
Functional studies with these human brain fractions allowed us to
directly demonstrate loss of CMA activity in AD brain lysosomes
that likely occur through a similar mechanism (disruption of
LAMP2A dynamics) to the one observed in our experimental
mouse models. One caveat of using human samples with
advanced AD pathology is that at late stages of the disease some
vulnerable neurons are already dead and therefore the signal that
is captured can arise from less vulnerable neurons and glia. To
minimize this problem, we selected the middle frontal gyrus
because this brain region displayed a low range of atrophy
(around 10%) compared to other brain regions such as the hippocampus or the entorhinal cortex (20 to 30%)68,69. However,
future studies at different stages of the disease and in other brain
regions are needed to better delineate the evolution of temporospatial changes in autophagy in AD.
In summary, our study reveals a complex interplay of acetylated
tau with different autophagic pathways that contributes to ﬁnetuning its intracellular levels. The inhibitory effect of acetylated tau
on CMA suggests that blockage of this selective form of autophagy
may contribute to neuronal toxicity and disease progression.
Therefore, enhancing CMA activity or preventing the arrival of
toxic forms of tau to CMA-active lysosomes, or promoting
degradation of rerouted tau inside LE/MVB could all be fruitful
options to prevent neurodegeneration in AD and other tauopathies.
Methods
Animals and cells. Adult male C57BL/6 mice were from Jackson Laboratory and
used under an animal study protocol approved by the Institutional Animal Care
and Use Committee (IACUC) of the Albert Einstein College of Medicine. The L2A
and Atg7 knockout mouse models were generated by crossing L2Aﬂox/ﬂox mice70 or
Atg7ﬂox/ﬂox mice71 with CamKinase II-Cre mice. Wild-type littermates were used
as control. Animals were maintained at 19–23 °C 30–60% relative humidity and
timer-controlled 12 h light/dark cycle. CSF was isolated from the cisterna magna of
controls and L2AKO mice using a glass capillary with negative pressure connected
to a micromanipulator to minimize blood contamination72. The mouse neuroblastoma cell line Neuro-2a (N2a) was a gift from Drs. Mandelkow (DZNE,
Germany), mouse embryonic ﬁbroblasts (MEFs) from wild-type (WT) or Atg5−/−
(KO) mice were a gift from Dr. N. Mizushima (The University of Tokyo). MEFs
14

from wild-type (WT) mice were generated in our labortatory73. Cells knocked
down for VPS4, were generated using the small interference RNA (siRNA) from
the Mission-Sigma library (Sigma-Aldrich) VPS4A (TRCN0000101417), VPS4B
(TRCN0000101821)43. Cells knocked down for Atg7 and LAMP2A were generated
using shRNA using the following sequences: ATG7: 5′-GATCCCCGCAGCTCA
TTGATAACCATTTCAAGAGAATGGTTATCAATGAGCTGCTTTTTC-3′ (for
Atg7) and 5′-CACCGCTGCAATCTGATTGATTATCGAAATAATCAATCAG
ATTGCAG-3′ (for LAMP2A)43,74. Cells were transfected using Lipofectamine
RNAiMAX Transfection Reagent (Invitrogen) in Opti-MEM media without antibiotics. Cells were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
(Sigma), in the presence of 10% fetal bovine serum (FBS), 50 μg/ml penicillin, and
50 μg/ml streptomycin at 37 °C with 5% CO2.
Transcription factor-mediated human neuron differentiation was induced from
a wildtype iPSC line with stable neurogenin 2 integration21. We followed a twostep protocol in which cells were transfected using Lipofectamine Stem
(Invitrogen) and transgenic cell populations were then selected and enriched
through cell-surface afﬁnity to magnetic streptavidin beads of a streptavidin
binding peptide fused to the low-afﬁnity nerve growth factor receptor75 and
generated 8 weeks old wildtype human neurons to detect tau release.
Human brain samples. Middle frontal gyri from European American brains were
obtained from the Charles F. and Joanne Knight Alzheimer’s Disease Research
Center. AD pathology was measured using Braak and Braak staging. The
Washington University IRB reviewed the Knight ADRC Neuropathology Core
(from where the brains were obtained) operating protocol, as well as this speciﬁc
study, and determined it was exempt from approval. In the state of Missouri,
individuals can give prospective consent for autopsy. Our participants provide this
consent by signing the hospital’s autopsy form. If the participant does not provide
future consent before death the DPOA or next of kin provide it after death. The age
of donors ranged from 70-80 years with an average age of 77.8 ± 3.2 years in
controls and from 73 to 95 years with an average age of 82.1 ± 2.1 years in AD
patients. The percentage of females was 43% in control and 60% in AD patients,
and the average postmortem interval of 12.5 ± 2.0 and 10.1 ± 1.2 h in control and
AD patients, respectively. The amount of tissue from each donor determined
whether the sample was used for isolation of autophagic vacuoles, lysosomes, or
late endosomes (although in most cases the three samples could be prepared).
Those samples with not enough tissue for isolation contributed to some of the
biochemical analysis with brain homogenates. Recruitment was not done as part of
this study and selection of the brain tissue from the repository was done on the
basis of the histopathology report (that assigned brain tissue as healthy control or
AD pathology) and the postmortem time (within the reported range) in order to
keep samples comparable. We are not aware of any bias in the selection of tissues
that could impact the results presented.
Chemicals and plasmids. Sources of reagents and chemicals were as described
before50,74,76. The antibodies against mouse LAMP-1 (clone 1D4B; 1:5000), human
LAMP-1 (clone H4A3; 1:5000), human LAMP-2 (clone H4B4; 1:5000), were from
the Developmental Hybridoma Bank (University of Iowa), against human LAMP2A (#ab18528; 1:5000) and GAPDH (#ab8245; 1:5000) from Abcam, against GST
(#136700; 1:1000) from Invitrogen, against hsp90 (#adi-spa-835-f; 1:1000) from
Stressgen, against actin (#A2066; 1:5000), FLAG (#F4042; 1:1000) and Vps4
(#sab4200025; 1:1000) from Sigma, against light chain 3 protein (LC3B, #2775,
1:1000), p53 (#2524s; 1:1000), Rab9 (#5133; 1:1000) and Atg7 (#2631; 1:1000) from
Cell Signaling, against GFP (#ta150052; 1:1000) from Origene, against hsc70 (clone
13D3, #NB120-2788; 1:1000) and Atg5 (#NB110-53818, 1:1000) from Novus,
against p62 (#BML-PW9860-0100; 1:2000) from ENZO, against BiP (#610978;
1:1000) from BD Transduction, against EEA-1 (#610456; 1:1000) from BD Biosciences, against NBR-1 (#H00004077-B01P; 1:1000) from Abnova. The antibody
against mouse LAMP-2A (1:7000) was developed in our laboratory40. The antibodies against total tau (DA9, 1:5000) and phosphorylated tau (PHF-1, 1:1000)
were a gift from Dr. P. Davies (The Feinstein Institute). The antibodies against
acetylated tau in lysines 174 (K174, 1:500) and 274 (K274, 1:500) were developed in
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Dr. Li Gan’s laboratory13,77. The antibody against human oligomeric tau (T22,
#ABN454, 1:1000) was from EMD Millipore. The antibody against Mucolipin was
a gift from Dr. R. Nixon (NYU). Human tau cDNA (1N4R) in the pRK172 vector
for puriﬁcation of recombinant tau was a gift from Dr. Mucke lab, Gladstone
Institutes. The mCherry-GFP-LC3 was generated by inserting the coding
sequence44 (1,1Kb) in the AtR2 and AtR1 sites of the pLX-301 plasmid using the
TOPO PCR Cloning kit (Invitrogen) with the following oligonucleotide primers:
5’ CACTGACAATTTCATCCCGAACGTCTCCTGGGAGG 3’ (for Topo-R) and
5’ CACCATGGTGAGCAAGGGCGAGGAGGAC 3’ (for Topo-D). Plasmids for
WT tau, tau K274,281Q12 were generated by site-directed mutagenesis (QuickChange kit from Agilent) in Human WT tau cDNA cloned into the pcDNA3.1
vector (Invitrogen) and site-directed mutagenesis (QuickChange kit from Agilent)
was used to generate tau K274,281Q by introducing A820C and A841C mutations
with the following oligonucleotide sequence: 5’ GGAGGCGGGCA GGTGCAGATAATTAATAAGCAGCTGGAT 3’. The eGFP-2a-huTau construct was cloned
in a pseudotype 2/8 AAV backbone, for efﬁcient neuronal tropism in the central
nervous system, under the chicken beta-actin (CBA) promotor58. The vector also
contains a woodchuck hepatitis virus posttranscriptional regulatory element
(WPRE – for long-term stable expression) and polyA sequence downstream of the
target gene. The AAV was produced at a titer of ~0.6×1013 infectious particles/mL
at the Mass Eye and Ear (MEEI) vector core (Boston, MA, USA).
Tau puriﬁcation and acetylation. Human tau cDNA (1N4R) was expressed in
BL21 (DE3) E. Coli and puriﬁed by ion-exchange chromatography. Brieﬂy, pelleted
bacteria were resuspended in PIPES buffer (50 mM PIPES, 1 mM EGTA, a protease
inhibitor (Sigma), pH 6.8), sonicated, and centrifuged at 27,000 × g for 15 min. The
supernatant was boiled at 95 °C for 10 min and after centrifugation at 100,000 × g
for 15 min, it was loaded into a column with P11 phosphocellulose resin (Whatman) and washed with 0.1 M NaCl in PIPES buffer, followed by elution with 0.3 M
NaCl in PIPES buffer. The puriﬁed recombinant tau proteins were assessed by
coomassie blue-stained SDS-polyacrylamide gel electrophoresis. In vitro acetylation
reaction was performed as previously described13 with minor modiﬁcations.
Brieﬂy, 1 μg of human recombinant tau, 2 μM of acetyl-CoA (Sigma), and 100 ng of
puriﬁed GST-p300 in acetylation buffer (50 mM HEPES, pH 8.0, 10% glycerol, 1
mM dithiothreitol (DTT), and 10 mM sodium butyrate) were incubated 4 h at 30 °
C with constant shaking. Control non-acetylated tau in these studies was incubated
in the same buffer but in absence of the GST-p300 enzyme.
Protein puriﬁcation. Hsc70 and DJA2 were expressed and puriﬁed using previously
reported methods78. Nucleotide free Hsc70 was prepared from several days of dialysis
in assay buffer (0.017% Triton X-100, 100 mM Tris-HCl, 20 mM KCl, and 6 mM
MgCl2, pH 7.4) at 4 °C to remove nucleotide. For tau puriﬁcations, the previously
reported protocol79 was used with the following modiﬁcations. Sodium chloride
(500 mM) and a chemical chaperone, betaine (10 mM), were included in the growth
media prior to induction to improve expression and minimize degradation products.
Expression was induced with 200 µM IPTG for 3.5 h at 30 °C and puriﬁed using
cation chromatography. Protein purity was conﬁrmed by SDS-PAGE analysis.
Tau binding ELISA. The method was adapted from a previous report80. Brieﬂy, 1
µM human hsc70 (30 µL) was immobilized overnight at 37 °C in clear, non-sterile
96-well plates (Thermo) in 50 mM MES (pH 5.5) and 0.5 mM DTT with 1 mM
ADP. Wells were washed with 100 µL of PSB-T (3 × 3 min., rocking) prior to the
addition of 30 µL of 4R0N tau or K280Q tau solution in binding buffer (40 mM
KCl, 8 mM MgCl2, 100 mM NaCl, 0.5 mM DTT, 0.01% Tween, and 25 mM acetate
for pH 5, 25 mM MES for pH 6, 25 mM HEPES for pH 7.4, and 25 mM Tris for pH
8) with 1 mM ADP for 3 h at RT. After blocking in 5% milk, quantiﬁcation of tau
binding was performed using rabbit anti-tau (H150) primary antibody (Santa Cruz,
sc-5587, 1:2000 in TBS-T, 50 µL/well) and goat anti-rabbit HRP-conjugated secondary (Anaspec, 28177, 1:2000 in TBS-T, 50 µL/well). TMB substrate (Cell Signaling, 7400 L) and 1 N HCl were used to detect binding. Absorbance was
measured using a SpectraMax plate reader (OD450). Minimal, non-speciﬁc binding
of tau to empty wells was subtracted as background, and curves were ﬁt using nonzero intercept hyperbolic ﬁts in Prism (GraphPad Software).
ATPase assay. The assay was adapted from previously reported methods81.
Brieﬂy, hsc70 (1 μM), 1 mM ATP, and increasing amounts of DJA2 were incubated
for 1–2 h in assay buffer (0.017% Triton X-100, 20 mM KCl, and 6 mM MgCl2,
with 100 mM acetate for pH 5, 100 mM HEPES for pH 7, and 100 mM Tris-HCl
for pH 7.4 and pH 8). Afterward, 80 µL of malachite green reagent was added for
phosphate detection followed by the addition of sodium citrate to halt nonenzymatic ATP hydrolysis. Absorbance was measured by a SpectraMax plate
reader (OD620) to determine phosphate concentration.
Isolation of subcellular fractions. CMA active lysosomes. Lysosomes with high
activity for CMA were isolated from rat liver, mouse brain, and from control and
AD patients brains by centrifugation of a light mitochondrial-lysosomal fraction in
a discontinuous metrizamide density gradient45. Homogenates were subjected to
low-speed centrifugation at 6800 × g for 5 min using a ﬁxed angle rotor and the
supernatant was further centrifuged at 17,000 g for 10 min to obtain a pellet
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enriched in light mitochondria and lysosomes. This pellet was washed in an excess
of 0.25 M sucrose and subjected to a second 17,000 × g spin for 10 min. The
resulting pellet was resuspended in 1.1 ml of 0.25 M sucrose and 2.2 ml of 85.6%
stock metrizamide solution (ﬁnal concentration: 57% metrizamide). This pellet
mixture was loaded at the bottom of an ultracentrifuge tube (14 × 89 mm, Beckman
ultra-clear centrifuge tube) and overlaid with a discontinuous metrizamide stepgradient in the following order: 2 ml of 32.8% metrizamide, 3.3 ml of 26.3%
metrizamide, and 3.6 ml of 19.8% metrizamide and was ﬁlled to the top with
0.25 M sucrose. Centrifugation was carried out in a Beckman Coulter Optima XL100K centrifuge using an SW41 rotor (Beckman) at 141,000 × g for 1 h (acceleration: 170 rpm/3 mins, deceleration: 170 rpm/4 mins). After centrifugation, four
separate bands (P1-4) were enriched in the following (from top to bottom): P1lysosomes active for CMA (CMA + lysosomes); P2-a mix of lysosomes active and
non-active for CMA (CMA + and CMA− lysosomes); P3-light mitochondria and
lysosomes; P4-light mitochondria. CMA+ and CMA− lysosomes were obtained by
collecting P1 and P2 separately and pelleting at 37,000 × g for 15 min in 10 volumes
of 0.25 M sucrose in a Beckman Allegra 64 R centrifuge, Then, the P2 pellet was
resuspended in MOPS/Sucrose buffer and centrifuged at 10,000 × g for 5 min at 4 °
C in an Eppendorf 5415C tabletop centrifuge. This procedure separated CMA+
lysosomes (retained in the supernatant) and CMA− lysosomes (pelleted down).
This supernatant was used to resuspend the P1 pellet. The CMA− lysosomes were
resuspended in an equivalent volume to the CMA+ lysosomes.
Cytosolic fractions were obtained by centrifugation for 1 h at 100,000 × g of the
supernatant obtained after separating the mitochondria-lysosome-enriched
fraction (the ﬁrst 17,000 × g spin).
Autophagic vacuoles. Fractions enriched in autophagic vacuoles were isolated
from mouse brains by centrifugation in a discontinuous metrizamide density
gradient by a modiﬁed method described before82. Brain homogenates were
initially centrifuged at 2000 × g for 5 mins in a Beckman Allegra 64 R centrifuge
(F0630 rotor) to pellet nuclei, unbroken cells, and plasma membrane, which was
resuspended in 0.25 M sucrose and centrifuged again in the same way. The ensuing
supernatants for each of these spins were then combined and subjected to
centrifugation at 17,000 × g for 12 mins. The resulting pellet was washed with
sucrose and the same spin was repeated. After this wash, the pellet was resuspended
in 0.95 ml of 0.25 M sucrose and adjusted to a ﬁnal concentration of 51%
metrizamide upon addition of 1.4 ml of 85.6% stock. This mixture was loaded at
the bottom of an ultra-clear centrifuge tube (14 × 89 mm, Beckman) and layered
with the following discontinuous metrizamide gradients: 4 ml of 26% metrizamide,
2 ml of 24%, 2 ml of 20%, and 2 ml of 15%. The gradient was topped with 0.25 M
sucrose and centrifuged in the Beckman Coulter Optima XL-100 K Ultracentrifuge
for 3 h 9 min at 105,000 × g (SW41 rotor, acceleration: 170 rpm/4 min,
deceleration: 170 rpm/4 min). After this spin, four bands were visible, at the
interphases enriched in the following fractions (starting at the top): fraction
1-AV10 (APG), fraction 2-AV20 (autolysosomes), fraction 3-LysC (low CMA
activity), fraction 4-light mitochondria. Finally, these bands were collected and
centrifuged at 24,000 × g for 10 mins in 10 volumes of 0.25 M sucrose in the
Beckman Allegra 64 R centrifuge (F0630 rotor) and the resulting pellets were
resuspended in 0.25 M sucrose.
Late endosomes. Isolation of brain late endosomes was obtained by
centrifugation of a mitochondrial-lysosomes-endosomal fraction in two
consecutive discontinuous Sucrose/Percoll gradients laid over a 2.5 M cushion by a
modiﬁed method described before83. Homogenates from animal brains obtained in
0.25 M Sucrose–1 mM EDTA, processed as described above, were subjected to lowspeed centrifugation at 2000 × g for 5 min in an F0630 rotor in a Beckman Allegra
64R centrifuge to sediment nuclei and unbroken cells, plasma membrane, and
heavy mitochondria. The supernatant was decanted and overlaid on top of the
ultracentrifuge tube (14 × 89 mm Beckman ultra-clear centrifuge tube) on a
discontinuous sucrose gradient as follows: 1 ml of 2.5 M sucrose, 9 ml of 27%
Percoll in SE buffer. Centrifugation was carried out in an SW41 rotor (Beckman) at
33,000 × g for 1 h and 5 min at 4 °C (acceleration: 170 rpm/3 min and deceleration:
170 rpm/4 min) using a Beckman Coulter Optima XL-100K ultracentrifuge.
Approximately 1 ml of the brown band (Golgi, late endosomes, and early
endosomes mixture) from the top of the 27% Percoll fraction was collected and
diluted with 1 ml of SE and overlaid on top of a discontinuous sucrose stepgradient as follows: 1 ml 2.5 M sucrose, 9 ml 10% Percoll in SE buffer.
Centrifugation was carried out in an SW41 rotor (Beckman) at 33,000 × g for 1 h
and 5 min at 4 °C (acceleration: 170 rpm/3 min and deceleration: 170 rpm/4 min)
using a Beckman Coulter Optima XL-100K ultracentrifuge. The top of 10% Percoll
(from the second gradient) was collected as Golgi and early endosomes and the
interface between 27% Percoll SE and 2.5 M sucrose (from the ﬁrst gradient) was
collected as late endosomes. Both fractions were pelleted twice at 100,000 × g for
10 min at 4 °C. The pellets were frozen at −80 °C or resuspended in appropriate
volume of 0.25 M sucrose for further experimentation.
Lysosomal membranes. Isolation of lysosomal membranes was done by
disruption of lysosomes through a hypotonic shock followed by 10 freeze-thaw
cycles in the presence of protease inhibitors. Matrix was recovered in the
supernatant upon centrifugation at 250,000 g for 1 h.

Intracellular protein turnover. To measure the degradation of long-lived proteins,
conﬂuent cells were labeled with 3H-leucine (2 μCi/ml) for 48 h at 37 °C,
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transfected with the indicated plasmids and then extensively washed and maintained in complete (10% FBS) or serum-deprived media containing an excess of
unlabeled leucine (2.8 mM) to prevent reutilization of radiolabeled leucine47. Aliquots of the media taken at different times were precipitated with TCA and proteolysis was measured as the percentage of the initial acid-insoluble radioactivity
(protein) transformed into acid-soluble radioactivity (amino acids and small
peptides) at the end of the incubation. Total radioactivity incorporated into cellular
proteins was determined as the amount of acid-precipitable radioactivity in labeled
cells immediately after washing.
Measurement of lysosomal activity. CMA activity in vitro was measured using
isolated intact lysosomes incubated with puriﬁed proteins and subjected to
immunoblot47. Binding was calculated as the amount of substrate protein bound to
the lysosomal membrane in the absence of protease inhibitors and uptake by
subtracting the amount of protein associated with lysosomes in the presence
(protein bound to the lysosomal membrane and taken up by lysosomes) and
absence (protein bound to the lysosomal membrane) of protease inhibitors.
CMA activity in intact cells was measured using lentivirus-mediated expression
of the KFERQ-PS-Dendra2 and high-content microscopy49. Cells were plated in a
96-well plate and photoactivated with a 405 nm light-emitting diode (LED: Norlux)
for 4 min with the intensity of 3.5 mA (current constant). After 16 h, cells were
ﬁxed with 4% paraformaldehyde, and images were captured with a high-content
microscope (Operetta system, Perkin Elmer) and quantiﬁcation was performed
with the manufacturer’s software in a minimum of 800 cells (approx. 9 ﬁelds).
LAMP-2A dynamics. Multimerization of LAMP-2A at the lysosomal membrane
was studied on 3–12% NativePAGE Bis-Tris Gels (Invitrogen) after solubilization
in 1% octylglucoside (in 20 mM MOPS and 150 mM NaCl buffer)41.
Measurement of endosomal microautophagy activity. e-MI activity in vitro was
measured using isolated late endosomes incubated with puriﬁed proteins and
subjected to immunoblot43. Binding and internalization were calculated as the
amount of substrate protein bound to the late endosomal membrane and intact
internal vesicles in the absence of protease inhibitors and luminal degradation by
subtracting the amount of protein associated with late endosomes in the presence
(protein bound to the endosomal membrane, intact internal vesicles and inside late
endosomal lumen) and absence (protein bound to the endosomal membrane and
intact internal vesicles) of protease inhibitors.
Intracranial injections. Adeno-associated viruses pseudotype 2/8 (AAV2/8)
encoding eGFP-2a-huTauP301L under the chicken β actin (CBA) were cloned and
produced at a titer ~0.6 × 1013 virus particles/mL59. AAVs were injected unilaterally in the right hippocampus above the CA1 region (A/P −2.0 mm, M/L: ±
1.5 mm, D/V from brain surface −1.5 mm) under standard aseptic surgery. One
microliter of the virus was injected using 34-gauge 10 µl Nanoﬁl (WPI, USA)
syringe and slowly infused at 0.2 µl/min using a UMP-III micropump (WPI, USA).
At completion, the needle was left in place for 5 min to allow diffusion of the viral
solution and avoid leakage.
Immunoﬂuorescence. For immunostaining of acetylated tau (anti-acK174), in
order to reduce the nonspeciﬁc nuclear staining, we ﬁrst pre-absorbed the antibody
by acetone Tau-knockout (KO) mice brain powder13. Brieﬂy, Tau KO mouse brains
were ﬁrst rinsed in 0.8% NaCl in Ca2+/Mg2+ free PBS, homogenized in 100 mM
MES, 1 mM EGTA, 0.5 mM MgCl2, 0.25 mM GTP at pH6.5, ﬁltered through the
ceramic ﬁlter, acetone-washed, and dried overnight. Mouse brains were sectioned
into 10-µm slices on a Leica CM1900 Cryostat. Antigen retrieval was ﬁrst performed
by heating the sections in 10 mM citric acid at a high-pressure cooker for 5 min. The
brain slices were then permeabilized in Tris-buffered saline (TBS) with 0.5% Triton
X-100 and blocked with 10% normal goat serum. For 3,3′-diaminobenzidine (DAB)
immunohistochemical staining, sections were quenched to suppress endogenous
peroxidase activity, followed by incubation with AC312. Immunoreactivity was
detected with 0.25 mg/ml DAB with 0.01% H2O2. Images were acquired on a brightﬁeld Leica DM5000B microscope with a Leica DFC310 FX camera.
For quantiﬁcation of tau spreading, mice were perfused with 0.9% sodium
chloride at 2, 4, and 8 weeks after surgery. The whole brain was extracted and postﬁxed overnight in 4% paraformaldehyde, and then cryoprotected in 20% sucrose/
PBS. Brains were ﬂash-frozen in isopentane, cut coronally at 40 µm in Leica CM
cryostat, and stored in PBS-0.2% sodium azide at 4 °C until processing. For
immunostaining, the ﬂoating brain sections were washed brieﬂy in PBS and then
permeabilized with 0.2% Triton X-100/TBS for 20 min at room temperature,
blocked in 5% normal goat serum (NGS)/PBS for 1 h at room temperature, and
then incubated with primary antibodies diluted in 3% NGS/PBS overnight at 4 °C:
mouse anti-human tau Tau13 (1:1000, abcam #ab19030), rabbit anti-human tau
TauY9 (1:1000, Enzo Life Science), rabbit anti-mouse GFAP (1:1000, abcam
#ab5804), goat anti-mouse Iba1 (1:1000, abcam #ab5076). After washing three
times with PBS, secondary antibodies were diluted in 3% NGS/PBS and applied for
1 h at room temperature: Alexa-555 anti-mouse, Alexa-555 anti-rabbit, Alexa 647
anti-mouse, and Alexa 647 anti-goat (1:2000, Thermo Fisher Scientiﬁc). After three
washes in PBS, sections were stained with Hoechst33342 (1:2000, Thermo Fisher
Scientiﬁc) for 2 min and then mounted on microscope glass slides with ProLong
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Diamond mounting media (Thermo Fisher Scientiﬁc). Images were acquired with a
Leica confocal TCS-SP8 (Leica Microsystem) using the Leica LAS-X software for
image adquisition and ImageJ Software (v.2.1.0) (NIH) was used for image
processing and analysis. Numbers of donor and recipient cells were manually
counted in the ipsilateral hippocampal formation by an experimenter blind to
genotypes.
RNA isolation and qPCR analyses. Total RNA was isolated using the RNeasy Plus
kit (Qiagen) or the RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Thermo
Fisher Scientiﬁc) according to the manufacturer’s instructions. For RNA extracted
from tissue sections, three 40µm-thick sections were selected per animal and the
right (injected) hippocampus was manually dissected. Total RNA was reverse
transcribed into cDNA using Superscript II (Invitrogen), and quantitative RT-PCR
analyses were performed using Podwer SYBR Green PCR Mix (Applied Biosystems) on a StepOne Plus Real-Time PCR System (Applied Biosystems) using the
primers shown in Supplementary Table 1. Thermal cycling conditions used were
according to the instruction of the SYBR Green mix protocol, and relative RNA
abundance was calculated using the comparative 2−ΔΔCt method84. Water was used
as the negative control for the qPCR analysis. All reactions were performed in
triplicates.
Electron microscopy. Isolated organelles were ﬁxed in 2.5% glutaraldehyde in 100
mM sodium cacodylate, pH 7.43 maintained isomolar by addition of 0.25 M
sucrose. Samples were post-ﬁxed in 1% osmium tetroxide in 100 mM sodium
cacodylate, pH 7.43, followed by 1% uranyl acetate. After ethanol dehydration and
embedment in LX112 resin (LADD Research Industries, 21210), ultrathin sections
were cut on a Reichert Ultracut E and were stained with uranyl acetate followed by
lead citrate. All grids were viewed on a JEOL 100CX II transmission electron
microscope at 80 kV.
General methods. Protein concentration was determined using the Lowry method
with bovine serum album as a standard85. Cells were solubilized on ice with RIPA
buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M
sodium phosphate, pH 7.2). Tissues were resuspended in 0.25 M sucrose buffer,
containing protease, phosphatase, and deacetylase inhibitors. Immunoblotting was
performed after transferring SDS-PAGE gels to nitrocellulose membranes86. Efﬁcacy and uniformity in the transference of proteins from the gel were conﬁrmed
using Ponceau red staining of the membranes. The proteins of interest were
visualized by chemiluminescence using peroxidase-conjugated secondary antibodies in LAS-3000 Imaging System (Fujiﬁlm). Densitometric quantiﬁcation of the
immunoblotted membranes was performed using Image J (NIH). When all samples
from a single experiment could not be ﬁt in a single gel, a ﬁxed amount of the same
sample was loaded at the beginning and end of each of the gels of the same set, and
the average value of both ﬂanking lines for each antibody was used for normalization when samples in different membranes were compared. A different grouping
of samples/conditions was also used in the replicates for those experiments to avoid
loading biases. Uncropped blots in the main and supplementary ﬁgures are shown
in Supplemental Figs. 7 and 8, respectively.
Statistical analysis, randomization, and sample size determination. All
numerical results are reported as mean ± s.e.m. and represent data from a minimum of three independent experiments unless otherwise stated. No data exclusion
was done in this study. In all instances n refers to individual experiments.
Experiments in cells in culture or those involving isolation of intracellular organelles were performed on different days to conﬁrm the reproducibility of the
procedures. In addition, recovery and enrichment for each subcellular fractionation
experiment were calculated to compare the purity and efﬁciency of isolations done
on different days. All independent replications were successful. For the studies in
live animals, the number of animals per group was determined through power
analysis using the information from similar studies from our group or collaborators
with similar methods32,58–61,70. For the studies performed in brain slices, cell lines
in culture, and in vitro assays, we determine the number of experimental repetitions to account for technical variability and changes in culture conditions based
on our previous studies using those systems32,45,59–61. For the studies using isolated
organelles from animals, the number of specimens used was determined based on
the average values of enrichment and recovery for the speciﬁc fraction using
endogenous markers for each compartment from our previous studies.45,60,61,70.
For the studies involving live animals, animals were randomly attributed to each
surgery group according to their genotype using the SELECT BETWEEN RANGE
function in Microsoft Excel. For the studies involving cells in culture or in vitro
assays with puriﬁed organelles, treatment groups were attributed randomly
between wells and plates to account for well or tube positioning effects. Immunoﬂuorescence/immunohistochemistry of protein levels was performed blinded to
their genotype or to the experimental group. For the morphometric analyses of the
electron microscopy samples, annotated micrographs were performed blinded. For
in vivo experiments, samples were blinded to the experimenter for the whole
experiment, image acquisition, and data analysis. Blinding was lifted only for the
ﬁnal statistical analysis.
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Basic data handling was performed using Microsoft Excel 365 (v.2101). Prior to
statistical testing, normality was assessed using the Shapiro Wilk test. Parameters
with two groups were compared using an unpaired, two-tailed t-test. Parameters
with more than two groups were compared using one-way ANOVA and Tukey’s
post-hoc analysis, Kruskal-Wallis test followed by Dunn’s post-hoc analysis or twoway ANOVA followed by Sidak post-hoc analysis with Prism software (v9-Graph
Pad Software Inc) or using Python (Python software foundation v.3.7.4 available at
https://www.python.org/) and the scientiﬁc python stack: scipy (v.1.3.1), numpy
(v.1.17.2), and matplotlib (v.3.1.1). Statistical analysis was performed in all the
assays, and signiﬁcant differences are noted in the graphical representations.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
There are no restrictions on data availability in this manuscript. Source data are provided
with this paper.
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